‘Resident Alien' Canceled at USA Network Ahead of Season 4 Finale
The sci-fi series first debuted in 2021 on Syfy but moved to USA after three seasons. 'Resident Alien' premiered on its second network in June with the start of Season 4. The series' fate has already been decided, but USA will air the final three episodes on their originally slated dates in the coming weeks.
More from Variety
'Rainmaker' Trailer: Rudy Baylor Goes on the Offensive in USA Network Legal Drama
'Andor': Alan Tudyk on K-2SO's Return, Filming 'Gruesome' Finale Scene and How Cassian 'Freed Him From His Servitude'
'Resident Alien' Season 4 Casts Stephen Root as Harry's Father (EXCLUSIVE)
'I knew going into it that this was likely going to be our final season,' series creator and showrunner Chris Sheridan told TV Insider, which was first to report on 'Resident Alien' ending. 'Creatively, that was exciting because I knew we could spend the time wrapping up some storylines and driving toward an ending. I'm so proud of how good Season 4 is and especially proud that we were able to finish as strongly as we did, with a finale that is probably my favorite episode of the series.'
Sheridan also promised that the Season 4 finale gives the series 'a very satisfying ending while also leaving the door cracked open for any future this world may have. I can't wait for everyone to see it.'
Alan Tudyk stars in 'Resident Alien' as an extra-terrestrial that has crash-landed on our planet with a mission to wipe out mankind. But, after stealing a small-town physician's identity, he starts to develop an affinity for Earthlings. The cast also includes Sara Tomko, Corey Reynolds, Alice Wetterlund, Levi Fiehler, Elizabeth Bowen, Judah Prehn and Meredith Garretson.
'Resident Alien' airs Fridays on USA, with new episodes available to stream on Peacock a week later. The series finale is slated for Aug. 8.
Best of Variety
New Movies Out Now in Theaters: What to See This Week
'Harry Potter' TV Show Cast Guide: Who's Who in Hogwarts?
Final Emmy Predictions: Talk Series and Scripted Variety - New Blood Looks to Tackle Late Night Staples
Solve the daily Crossword
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
27 minutes ago
- Yahoo
Fantasy Football TE Draft Strategy: Focus on the players who cosplay as wide receivers
I love going to gaming conventions. I know. Shocker, right? The guy with an engineering background who writes about fantasy football likes video games. And, yes, seeing new ways to get my sons into RPGs or real-time strategy adventures will always pique my interest. But I'm there for the cosplay. You can tell who's into bringing their favorite characters to life by their costume. Anything with LEDs, moving parts, or a frame-altering structure stands out. Or, said differently, we know what matters when we see it. The same is true for the tight end position. [Join or create a Yahoo Fantasy Football league for the 2025 NFL season] Our draft strategies around TEs focus on the guys who cosplay as receivers. The traits to prioritize are hard to miss. But only so many make a true difference each season. However, by knowing what to target throughout the draft, you can address the position without impacting your roster. Taking a TE in the Early Rounds Pros: Weekly upside at a onesie position Cons: Potential for weaker starters at WR or RB On the one hand, taking an early-round TE makes in-season roster decisions a breeze. You're only concern is their bye week. Plus, with how often they get the ball, you'll see their highlights plastered across social media. Players like Brock Bowers are receivers with a TE designation. They're the cheat code at the position. Luckily, like most good cosplayers, they're easy to spot. 'Athletic' is the common descriptor. But after looking at the last five seasons of data, I'll call them 'opportunistic.' Avg. Target Share (for Top-3 TEs): 21.7% Targets per Route Run: 23.6% Yards per Route Run: 1.97 Since 2020, only four TEs to cap the fantasy season with a top-3 finish have had a target share under 20.0%. Unsurprisingly, their volume and efficiency metrics align with most of our favorite receivers. Bowers and CeeDee Lamb generated almost the same amount of yards after the catch on a per-reception basis (5.3 and 5.4). Trey McBride (8.7) saw more targets per game than Amon-Ra St. Brown (8.1). And George Kittle ranked fourth amongst receivers and TEs in red-zone TDs. All three would've had top-20 seasons in PPR leagues if they had a 'WR' next to their name. However, if you want one of them this year, you'll have to pay up. I talked about being cognizant of opportunity cost last week as I went over my QB draft strategy. Essentially, we're giving up a shot at a starting RB or WR to fill a onesie spot. And our chances of hitting on a productive player diminish each round. But if the data doesn't sway you, let's play a game of Either/Or. Either Brock Bowers or one of Drake London/Bucky Irving Either Trey McBride or one of Ladd McConkey/Chase Brown Either George Kittle or one of Tee Higgins/James Cook By Yahoo's ADP, the early-round TEs will force you to choose between them and a weekly staple at either core position. But there's a workaround. Contextualizing each player's potential workload allows you to find one or multiple options later with a similar range of outcomes. Instead of Chase Brown, draft Kenneth Walker (for rushing volume) and James Conner (with pass-catching upside). As a result, you can escape the first six rounds with a high-end TE along with a viable nucleus of WRs and RBs. [Subscribe to Yahoo Fantasy Plus and unlock Instant Mock Drafts today] Mark Andrews, Ravens Drafting a Mid-Round TE Pros: Enables a strong starting roster with minor depth Cons: Weekly projections will favor holding your TE despite weak production I went to PAX East once dressed as a Black Mesa scientist (shoutout to my nerds who know the reference). All I needed was a lab coat with the logo on it. I looked sharp, even got some comments. But I wasn't anything compared to the guy with a full-on Transformers costume. Like my attempt at cosplay, mid-round TEs are the next best thing to the elite options. They play the part well, but they've got at least one glaring issue keeping them out of the early rounds. Last year's TE10 is a perfect example. First off, I wasn't a Motorhead fan before today. I get it now. Anyway, Tucker Kraft exploded onto the scene as the value TE to draft. His pre-draft testing signaled he could be a menace on the field. And the South Dakota State product delivered. Kraft's absurd average of 9.3 yards after the catch per reception is the second-most of any TE over the last 10 years. The only problem is his situation. Target Share: 15.1%, 13th (out of 27 qualifying TEs, min. 50.0% route rate) Targets per Route Run: 16.1%, 21st Yards per Route Run: 1.63, 6th Kraft is part of an offense featuring multiple WRs, sitting around the league average in pass rate over expectation. Simply put, the pie is small, and so is his slice of it. But you can find warts on his peers. Zach Ertz saw the seventh-most targets of any TE, but (famously) has trouble generating more yards past the catch. A.J. Brown and DeVonta Smith keep Dallas Goedert's ceiling in check. Kyle Pitts ... never mind. However, the silver lining is their usage in the red zone. Zach Ertz: 26 (RZ targets), T-3rd (out of 27 qualifying TEs, min. 50.0% route rate) Jonnu Smith: 25, 5th Hunter Henry: 23, T-7th Kyle Pitts: 17, T-11th Tucker Kraft: 17, T-11th Falling into the end zone (with the ball) is what gives a mid-round TE fantasy relevance. For the tight ends in the back half of 2024's top 12, touchdowns alone accounted for 18.8% of their scores. David Njoku's five scores allowed him to sneak into the TE11 spot after nearly matching career lows in receiving efficiency. Cole Kmet finding the paint seven times in '22 propelled him to TE8 despite only having 544 receiving yards on the season. In either case, identifying TEs that are still a part of the passing game when their team is in scoring position offers not only a weekly floor, but access to a ceiling with top-12 upside each week. Jake Ferguson, Cowboys; Tyler Warren, Colts; Chig Okonkwo, Titans Gambling at TE in the Late Rounds Pros: Supports a (mostly) full roster build with starters and depth Cons: Week-to-week variability at TE will require constant matchup evaluation Consider late-round TEs as matchup-based starters. Every Tuesday night (or whichever night is before your waivers process), you'll need to look at the defense your starter will face in the coming days. From there, it's either keep him or stream another in a better environment. However, instead of putting in claims based on vibes, I've got some math to guide you. Target Share: 0.62 (r-squared) TPRR: 0.34 Route Rate: 0.27 (Team-Level) Yards per Drive: 0.18 (Team-Level) EPA per Play: 0.12 (Team-Level) Pass Rate Over Expectation: 0.11 I ran a study using five years of data to examine the correlation between each metric and fantasy points. The closer to 1.0, the stronger the connection. Intuitively, more targets get you more points. Surprisingly, their team situation isn't much of a factor. However, most (read all) of the TEs with secure target shares are off the board. So, let's drop down to another stat worth valuing. Routes signal intent by a play-caller to have a receiver involved in a play concept. Afterward, it's on the player to get the ball thrown their way. But it won't happen with them on the sideline. Accordingly, we have to do some detective work to see which TEs will even be on the field. Practice reports can help in this regard. Yes, the Jets' offense is a work in progress at best. However, Mason Taylor profiles as an athletic outlet for Justin Fields on a team featuring 30-year-old Josh Reynolds and Tyler Johnson, who signed a $1.3M contract in free agency. In other words, Taylor's potential to see the field should be high. We'll need to see his rapport with Fields to assess his value over the season, but starting with his participation within the offense should be our first clue. Theo Johnson, Giants; Ja'Tavion Sanders, Panthers
Yahoo
27 minutes ago
- Yahoo
Is Disney Stock a Magical Buy After Earnings?
Entertainment leader The Walt Disney Company (DIS) recently reported solid profitability gains in its third-quarter results. The company also stands on the cusp of a significant acquisition of the NFL Network. With Q3 results in the rearview and an exciting deal on the way, should investors play DIS stock now? Or should they hold off on buying shares of the entertainment giant? More News from Barchart Why This Cannabis Penny Stock Could Be Wall Street's Next Meme Trade Breakout Apple Stock Is Gaining Momentum, Is AAPL Stock a Buy? Peter Thiel-Backed Bullish Is About to IPO. Should You Buy BLSH Stock? Our exclusive Barchart Brief newsletter is your FREE midday guide to what's moving stocks, sectors, and investor sentiment - delivered right when you need the info most. Subscribe today! About Disney Stock Founded in 1923, the Walt Disney Company is a global leader in the entertainment and media industries. Headquartered in Burbank, California, the company owns iconic brands such as Disney, Pixar, Marvel, Star Wars, and National Geographic. Its operations encompass television broadcasting, film production, merchandise licensing, and digital platforms, including Disney+. The company also runs internationally renowned theme parks and resorts. Disney has a market capitalization of $209 billion. A transformation is underway in Disney's sports segment, with its ESPN subsidiary launching a sports streaming service for customers on Aug. 21. This service brings the full suite of ESPN's network under one umbrella. The launch of the service is timed to coincide with numerous sports events, including the start of the NFL season. This also brings the bombshell news that ESPN would be acquiring the NFL Network, which has nearly 50 million subscribers, and other media assets. The addition of the NFL streaming rights gives the company more leverage for its upcoming sports streaming service. Over the past 52 weeks, DIS stock has gained 34% as the company experiences growth in subscribers. DIS stock reached a 52-week high of $124.69 in late June but is now 8% off that mark. So far this year, the stock is up by nearly 4%. Right now, shares of Disney trade at an attractive valuation. Its price sits at 19.3 times forward earnings, which is lower than the current industry average. Disney's Profits Climbed in the Third Quarter Disney reported robust third-quarter results for fiscal 2025 on Aug. 6. The company's revenue increased by 2% from the prior-year period to $23.65 billion. However, this figure fell just short of the $23.68 billion that Wall Street analysts were expecting. At the heart of the growth was Disney's growing subscriber count in its streaming services and growth in its domestic theme parks segment. The company's total Disney+ subscribers for the quarter were 127.8 million, increasing 1.4% from the prior quarter. This subscriber growth was, in turn, fueled by a 2.5% sequential increase in international subscriber count, while domestic subscriber growth (in the U.S. and Canada) remained flat. Its total Hulu subscriber count grew by 1.5% sequentially to 55.5 million. Disney's direct-to-consumer (DTC) segment's operating income stood at $346 million, representing a significant turnaround from the $19 million operating loss it had reported a year earlier. On top of that, the experiences segment's operating income climbed by 13% year-over-year (YOY) to $2.52 billion. The company also reported gains in its profitability as its operational metrics grew. Adjusted EPS grew by 16% YOY to $1.61, which was higher than the $1.46 per share that Wall Street analysts were expecting for the quarter. For Q4, Disney expects total Disney+ and Hulu subscriptions to increase by more than 10 million compared to the third quarter. The majority of the growth is likely to come from Hulu due to its expanded Charter deal, while the Disney+ subscriber count is expected to grow modestly. For the current fiscal year, Disney expects adjusted EPS to be $5.85, representing an 18% increase from the prior year. Its DTC segment is forecast to report an operating income of $1.30 billion. Wall Street analysts are soundly optimistic about Disney's future earnings. For the current fiscal year, EPS is projected to increase 18.3% annually to $5.88, followed by 10% growth to $6.47 in the next fiscal year. What Do Analysts Think About Disney Stock? In the eyes of Wall Street analysts, Disney remains a sweetheart in the entertainment industry. Recently, Rosenblatt raised its price target on DIS stock from $140 to $141, while maintaining a 'Buy' rating. The price target revision came after the company's Q3 report, with Rosenblatt analysts highlighting its theme park growth. Needham analyst Laura Martin also maintained a 'Buy' rating on DIS stock with a $125 price target. The rating is based on several positive developments, such as Disney's recent profitability gains. Reflecting positive sentiment, Evercore ISI Group analyst Vijay Jayant maintained an 'Outperform" rating, hiking the price target from $134 to $140. Expecting the company to continue its track of sustained earnings growth, Morgan Stanley analyst Benjamin Swinburne raised the price target from $120 to $140 as well, with an unchanged 'Outperform' rating. Disney remains a favorite on Wall Street, with analysts awarding it a consensus 'Strong Buy' rating overall. Of the 28 analysts rating the stock, a majority of 20 analysts rate it a 'Strong Buy,' two analysts suggest a 'Moderate Buy,' and six play it safe with a 'Hold' rating. The consensus price target of $134.52 represents 17% potential upside from current levels. The Street-high price target of $152 indicates 32% potential upside from here. The Bottom Line Disney's operations might be in a growth phase at the moment, with growing subscribers and additions in theme parks, such as the company's planned seventh theme park set to be built in Abu Dhabi. Disney's bottom-line gains are also notable. Therefore, investors may want to consider DIS stock now. On the date of publication, Anushka Dutta did not have (either directly or indirectly) positions in any of the securities mentioned in this article. All information and data in this article is solely for informational purposes. This article was originally published on Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Business Wire
28 minutes ago
- Business Wire
CEL-SCI Reports Fiscal Third Quarter 2025 Financial Results
VIENNA, Va.--(BUSINESS WIRE)--CEL-SCI Corporation (NYSE American: CVM) today reported financial results for the three months ended June 30, 2025, as well as key recent clinical and corporate developments. 'Commercial and regulatory momentum for Multikine is accelerating due to three driving factors—our partnership negotiations in Saudi Arabia, the increasing interest in CEL-SCI from investors in the Middle East, and continued recognition in the global scientific and regulatory community that PD-L1 is a valuable predictive marker for head and neck cancer,' stated CEL-SCI CEO, Geert Kersten. 'We are particularly encouraged about the potential for Multikine to become commercially available in Saudi Arabia in 2025. Should this happen, we believe it could support our regulatory and commercial efforts worldwide.' Corporate and Clinical Developments include: CEL-SCI's CEO and a Director of the Company each purchased a combined total of 32,116 shares of restricted common CEL-SCI stock in July 2025. Gross proceeds of approximately $5.7 million were raised by CEL-SCI in July 2025 through the sale of 1,500,000 shares of common stock at an offering price of $3.82 per share, priced at-the-market under NYSE American rules. In May of 2025, the Company raised gross proceeds of $5 million through the sale of 2,000,000 shares of common stock priced at $2.50 per share. CEL-SCI is set to sign a commercialization and regulatory partnership agreement with a leading Saudi Arabian pharmaceutical company for Multikine* (Leukocyte Interleukin, Injection) in the treatment of head and neck cancer in the Kingdom of Saudi Arabia. A Breakthrough Medicine Designation application for Multikine was filed by the pharma partner with the Saudi Food and Drug Authority (SFDA). According to the SFDA, the response time to a Breakthrough Medicine Designation application is approximately 60 days. Following the granting of the Breakthrough Medicine Designation, Multikine would immediately become available for patient access and reimbursement/sale in Saudi Arabia. Several leading Saudi funds have expressed interest in investing in CEL-SCI, Multikine and/or a potential joint venture to serve the wider Middle East and North Africa (MENA) market. CEL-SCI's offering with Multikine is in line with Saudi Arabia's Vision 2030 initiative which seeks to make the Kingdom a global biotech hub. Given the SFDA's 60-day timeline to make Multikine potentially available, in-country investors have expressed interest in bringing a much-needed cancer treatment to market while also supporting their nation's health-tech goals. A new study supports CEL-SCI's strategy to seek early approval in the U.S. CEL-SCI is in final preparations before starting enrollment of its 212-patient Confirmatory Registration Study for Multikine in newly diagnosed locally advanced head and neck cancer patients. The U.S. Food and Drug Administration (FDA) has given CEL-SCI the go-ahead for the study. CEL-SCI plans to seek early approval based on early tumor responses. A third-party study recently published in Cancer Cell titled 'Distinct CD8+ T cell dynamics associate with response to neoadjuvant cancer immunotherapies' provides support for CEL-SCI's approach. The concept that tumor responses predict survival has been acknowledged for many cancer types and has led to accelerated approval of many cancer drugs. The third-party study published in Cancer Cell gives further support that this is also true in the neoadjuvant pre-surgical immunotherapy treatment of head and neck cancer. More data on PD-L1 as a predictive biomarker signals a clear regulatory pathway for Multikine in PLD-L1 negative patients. There is a growing body of data on PD-L1 as a predictive biomarker and diagnostic for cancer. In June, the FDA approved Merck's KEYTRUDA® (pembrolizumab), an anti-PD-L1 therapy, for the treatment of adult patients with resectable locally advanced head and neck squamous cell carcinoma (HNSCC) whose tumors express PD-L1. Of note, the FDA granted Merck priority review in February 2025 and approval in June 2025 based on interim results. This sets a positive precedent for Multikine in PD-L1 low and negative patients. Multikine reduced the risk of death by 66% compared to standard of care in the target population of patients with low and zero PD-L1, while Keytruda reduced the risk of recurrence and progression (EFS) by only 30% compared with standard of care in patients whose tumors expressed higher PD-L1 without demonstrating improvement in overall survival. Financial Results During the three months ended June 30, 2025, net loss available to common shareholders was $5.7 million compared to $7.5 million in the prior year period. Basic and diluted net loss per common share was $1.36 for the three months ended June 30, 2025, compared to $4.18 for the three months ended June 30, 2024. In demonstration of his deep commitment to the Company and Multikine's potential to significantly improve patient outcomes, CEO Geert Kersten has been and is currently working without taking a salary. About CEL-SCI Corporation CEL-SCI believes that boosting a patient's immune system while it is still intact should provide the greatest possible impact on survival. Multikine is designed to help the immune system "target" the tumor before surgery, radiation and chemotherapy because that is the time when the immune system is still relatively intact and thereby thought to be better able to mount an attack on the tumor. Multikine (Leukocyte Interleukin, Injection), a true first-line cancer therapy, has been dosed in over 740 patients and received Orphan Drug designation from the FDA for neoadjuvant therapy in patients with squamous cell carcinoma (cancer) of the head and neck. Based on the data from the completed randomized controlled Phase 3 study of 928 patients, the FDA concurred with CEL-SCI's target patient selection criteria and gave the go-ahead to conduct a confirmatory Registration Study which will enroll 212 patients. CEL-SCI will enroll newly diagnosed locally advanced not yet treated resectable head and neck cancer patients with no lymph node involvement (determined via PET scan) and with low PD-L1 tumor expression (determined via biopsy), representing about 100,000 patients annually. The Company has operations in Vienna, Virginia, and near/in Baltimore, Maryland. Forward-Looking Statements This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. When used in this press release, the words "intends," "believes," "anticipated," "plans" and "expects," and similar expressions, are intended to identify forward-looking statements. Such statements are subject to risks and uncertainties that could cause actual results to differ materially from those projected. Factors that could cause or contribute to such differences include an inability to duplicate the clinical results demonstrated in clinical studies, timely development of any potential products that can be shown to be safe and effective, receiving necessary regulatory approvals, difficulties in manufacturing any of the Company's potential products, inability to raise the necessary capital and the risk factors set forth from time to time in CEL-SCI's filings with the Securities and Exchange Commission, including but not limited to its report on Form 10-K for the year ended September 30, 2024. The Company undertakes no obligation to publicly release the result of any revision to these forward-looking statements which may be made to reflect the events or circumstances after the date hereof or to reflect the occurrence of unanticipated events. * Multikine (Leukocyte Interleukin, Injection) is the trademark that CEL-SCI has registered for this investigational therapy. This proprietary name is subject to FDA review in connection with the Company's future anticipated regulatory submission for approval. Multikine has not been licensed or approved for sale, barter or exchange by the FDA or any other regulatory agency. Similarly, its safety or efficacy has not been established for any use.
